Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM120 for hyperemesis gravidarum
ACTRN12624001421527Phase 2Active, not recruiting
- Sponsor
- NGM Biopharmaceuticals
- Start
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, single-blind trial of NGM120 in hyperemesis gravidarum (HG) (2 arms), sponsored by NGM Biopharmaceuticals. Primary endpoint: Safety and tolerability composite outcome. Started Feb 2025; status: active, not recruiting.
02
Drugs
NGM120
03
Conditions
hyperemesis gravidarum (HG)
Beyond the preview
Go deeper on ACTRN12624001421527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001421527.